CoChat

Factors Impacting Efficacy of AAV-Mediated CRISPR-Based Genome Editing for Treatment of Choroidal Neovascularization

Open access
Chung, Sook Hyun, Mollhoff, Iris Natalie, Nguyen, Uyen, Nguyen, Amy, Stucka, Natalie, Tieu, Eric, Manna, Suman, Meleppat, Ratheesh Kumar, Zhang, Pengfei, Nguyen, Emerald Lovece, Fong, Jared, Zawadzki, Robert, Yiu, Glenn · 2020 · Molecular Therapy - Methods & Clinical Development
Cited by 34

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Frequent injections of anti-vascular endothelial growth factor (anti-VEGF) agents are a clinical burden for patients with neovascular age-related macular degeneration (AMD). Genomic disruption of VEGF-A using adeno-associated viral (AAV) delivery of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 has the potential to permanently suppress aberrant angiogenesis, but the factors that determine the optimal efficacy are unknown. Here, we investigate two widely used Cas9 endonucleases, SpCas9 and SaCas9, and evaluate the relative contribution of AAV-delivery efficiency and genome-editing rates in vivo to determine the mechanisms that drive successful CRISPR-based suppression of VEGF-A, using a mouse model of laser-induced choroidal neovascularization (CNV). We found that SpCas9 demonstrated higher genome-editing rates, greater VEGF reduction, and more effective CNV suppression than SaCas9, despite similar AAV transduction efficiency between a dual-vector approach for SpCas9 and single-vector system for SaCas9 to deliver the Cas9 orthologs and single guide RNAs (gRNAs). Our results suggest that successful VEGF knockdown using AAV-mediated CRISPR systems may be determined more by the efficiency of genome editing rather than viral transduction and that SpCas9 may be more effective than SaCas9 as a potential therapeutic strategy for CRISPR-based treatment of CNV in neovascular AMD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtm.2020.01.006

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 34

Metadata

Authors
Chung, S. H., Mollhoff, I. N., Nguyen, U., Nguyen, A., Stucka, N., Tieu, E., Manna, S., Meleppat, R. K., Zhang, P., Nguyen, E. L., Fong, J., Zawadzki, R., & Yiu, G.
Venue
Molecular Therapy - Methods & Clinical Development
Publisher
Elsevier BV
Published
2020-06
Volume
17
Pages
409-417
ISSN
2329-0501 (ISSN-L)
OpenAlex
W3001652577
Cited by
34
References
17
FWCI
1.73
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Factors Impacting Efficacy of AAV-Mediated CRISPR-Based Genome Editing for Treatment of Choroidal Neovascularization. https://app.cochat.ai/papers/10.1016/j.omtm.2020.01.006
The paper
Chung, S. H., Mollhoff, I. N., Nguyen, U., Nguyen, A., Stucka, N., Tieu, E., Manna, S., Meleppat, R. K., Zhang, P., Nguyen, E. L., Fong, J., Zawadzki, R., & Yiu, G. (2020). Factors Impacting Efficacy of AAV-Mediated CRISPR-Based Genome Editing for Treatment of Choroidal Neovascularization. Molecular Therapy - Methods & Clinical Development. https://doi.org/10.1016/j.omtm.2020.01.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.